Business Context and Reporting Period
Company: BioCardia, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2024
Reporting Period: Specific event date of July 17, 2024.
The filing reports a corporate event regarding intellectual property rather than a standard financial reporting period.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the issuance of a new U.S. Patent:
- Patent Number: 12,036,371
- Title: "Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter"
- Technology: Relates to medical methods for transseptal access to the heart using steerable introducers based on the Company's Morph DNA technology.
- Expiration: The patent term will expire in 2035.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the general context of the patent issuance. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the scope and enforceability of U.S. Patent No. 12,036,371 regarding transseptal access methods.
- Confirm the commercial application timeline for the Morph DNA technology covered by this patent.
- Review the attached press release (Exhibit 99.1) for additional details on the patent's strategic importance.
- Check subsequent filings for any financial impact or licensing agreements related to this intellectual property.